Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior.
Gantois I, Fang K, Jiang L, Babovic D, Lawrence AJ, Ferreri V, Teper Y, Jupp B, Ziebell J, Morganti-Kossmann CM, O'Brien TJ, Nally R, Schütz G, Waddington J, Egan GF, Drago J. Gantois I, et al. Among authors: nally r. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4182-7. doi: 10.1073/pnas.0611625104. Epub 2007 Feb 28. Proc Natl Acad Sci U S A. 2007. PMID: 17360497 Free PMC article.
Ethologically based resolution of D2-like dopamine receptor agonist-versus antagonist-induced behavioral topography in dopamine- and adenosine 3',5'-monophosphate-regulated phosphoprotein of 32 kDa "knockout" mutants congenic on the C57BL/6 genetic background.
Nally RE, Kinsella A, Tighe O, Croke DT, Fienberg AA, Greengard P, Waddington JL. Nally RE, et al. J Pharmacol Exp Ther. 2004 Sep;310(3):1281-7. doi: 10.1124/jpet.104.068957. Epub 2004 May 12. J Pharmacol Exp Ther. 2004. PMID: 15140917
Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction 'knockout'.
Tomiyama K, Makihara Y, Yamamoto H, O'Sullivan G, Nally RE, Tighe O, Kinsella A, Fienberg AA, Grandy DK, Sibley DR, Croke DT, Koshikawa N, Waddington JL. Tomiyama K, et al. Among authors: nally re. Eur Neuropsychopharmacol. 2006 Aug;16(6):437-45. doi: 10.1016/j.euroneuro.2005.11.012. Epub 2006 Jan 18. Eur Neuropsychopharmacol. 2006. PMID: 16413758
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
Harris V, Holmes J, Gbinigie-Thompson O, Rahman NM, Richards DB, Hayward G, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Ahmed H, Carson-Stevens A, Nguyen-Van-Tam JS, Patel MG, Saville BR, Francis N, Thomas NPB, Evans P, Dobson M, Png ME, Lown M, van Hecke O, Jani BD, Hart ND, Butler D, Cureton L, Patil M, Andersson M, Coates M, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Yu LM, Hobbs FDR, Little P, Butler CC; PANORAMIC Trial Collaborative Group. Harris V, et al. Lancet Infect Dis. 2025 Jan;25(1):68-79. doi: 10.1016/S1473-3099(24)00431-6. Epub 2024 Sep 9. Lancet Infect Dis. 2025. PMID: 39265595 Free article. Clinical Trial.
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, Helman L, Park DW, Schwarz TF, Melendez IMG, Schaefer A, Roy N, Stephan B, Molnar D, Kostanyan L, Powers JH 3rd, Hulstrøm V; Members of the AReSVi‐006 Study Group. Curran D, et al. Influenza Other Respir Viruses. 2024 Feb 3;18(2):e13236. doi: 10.1111/irv.13236. eCollection 2024 Feb. Influenza Other Respir Viruses. 2024. PMID: 38314063 Free PMC article. Clinical Trial.
38 results